Browse the evidence

Changes in body composition at menopause influence risks of various health issues including cardiovascular disease and mental health disorders.

Health professionals should monitor and address the increased health risks associated with body composition changes during menopause.

Tirzepatide induced a mean absolute HbA1c reduction across the three doses ranging from 2.3% to 3.0% in East Asian participants with type 2 diabetes.

Tirzepatide is effective in reducing HbA1c levels in East Asian individuals with type 2 diabetes.

GLP-1 receptor agonists (GLP-1 RAs) may improve obstructive sleep apnea (OSA) symptoms by reducing fat deposition around the upper airway and decreasing systemic inflammation.

Practitioners may consider GLP-1 RAs as a potential treatment option for improving OSA symptoms in obese patients.

GLP-1 RAs may enhance traditional OSA treatments, offering an integrated approach targeting the root cause of obesity in OSA.

Practitioners should consider integrating GLP-1 RAs into OSA management strategies.

GLP-1 RAs may provide benefits for other obesity-related comorbidities, including hypertension and cardiovascular disease.

Practitioners should be aware of the potential for GLP-1 RAs to address comorbidities in obese OSA patients.

Obesity contributes to the emergence of cardiovascular risk factors such as dyslipidaemia, type 2 diabetes, hypertension, and sleep disorders.

Addressing obesity may help in managing these associated cardiovascular risk factors.

Bariatric surgery before liver transplantation is feasible and can improve liver function for patients on the transplant waiting list.

Bariatric surgery may be a beneficial option for patients with obesity awaiting liver transplantation to enhance liver function.

Low intracellular ATP levels lead to carbohydrate-dependent hunger and impaired satiety.

Recognizing the link between ATP levels and hunger can aid in obesity treatment strategies.

Twenty percent (n = 24) of the five-year completers achieved remission from type 2 diabetes.

Practitioners can consider very low carbohydrate diets as a viable option for achieving diabetes remission.

Tirzepatide treatment resulted in a significant decrease of bodyweight compared with the vehicle treatment.

Tirzepatide may be effective for weight management in obese populations.

Broad changes in the inflammatory proteome were observed among the study cohort with initial weight loss of ≈8 kg from a median 94 kg at study entry.

Practitioners should consider the role of inflammatory proteins in weight loss and maintenance strategies.

Visceral obesity is correlated with cardiometabolic diseases and higher mortality.

Monitoring visceral fat levels can be crucial for assessing mortality risk.

PGDP levels at the 3-month visit were positively correlated with improvements in fat mass, glycaemia, lipaemia, and liver function.

Monitoring PGDP levels may provide insights into metabolic improvements in patients undergoing treatment.

Baseline metabolite profiling enhanced prediction accuracy for CLA-induced body composition benefits.

Practitioners can use baseline metabolite profiles to better predict individual responses to CLA supplementation.

The menstrual cycle-based training group (MC) showed a significant increase in fat free mass (FFM) of 1.7 ± 1.8 kg, but this was not statistically significant (P = 0.080).

Practitioners may consider menstrual cycle-based training for potential benefits in body composition.

Alanine aminotransferase levels decreased with GLP-1RA and combination therapy.

Practitioners may consider monitoring liver enzyme levels when prescribing GLP-1RAs and combination therapy.

Four nights of sleep restriction reduced low-dose insulin glucose infusion rate (GIR) by 20% and high-dose insulin GIR by 12% in postmenopausal women.

Practitioners should consider the impact of sleep restriction on insulin sensitivity in postmenopausal women.

The metabolic changes induced by GLP-1 agonists can impact adipose and muscle tissue, leading to changes in facial contour and overall appearance.

Understanding these metabolic changes can help practitioners manage patient expectations regarding facial aesthetics.

Individuals with obesity are at greater risk for developing metabolic diseases such as type 2 diabetes, metabolic dysfunction-associated steatohepatitis, and cardiovascular diseases.

Healthcare providers should monitor metabolic health in patients with obesity.

Lifestyle modification alone is often insufficient to achieve clinically meaningful weight loss.

Clinicians should consider pharmacotherapy in conjunction with lifestyle changes for effective weight management.

Bariatric surgery offers glycemic improvements and potential remission of early onset diabetes, but weight loss results are lower in patients with diabetes compared to those without.

Practitioners should be aware that while bariatric surgery can improve glycemic control, the weight loss outcomes may not be as significant for patients with diabetes.

High overall or unhealthful low-fat diet (LFD) scores are associated with increased likelihood of steatosis (OR = 1.65 for overall LFD, OR = 1.41 for unhealthful LFD).

Avoiding high scores in unhealthful low-fat diets may reduce the risk of hepatic steatosis.

Using LNCSBs as a substitute for SSBs was associated with small improvements in cardiometabolic risk factors without evidence of harm.

Practitioners can consider LNCSBs as a safe alternative to SSBs for improving health outcomes.

Protein interacts with carbohydrates, fats, and dietary energy density to influence calorie intake and metabolic physiology.

Understanding protein's role can help in designing effective dietary interventions.